
## WHAT IS CLAIMED IS:

- 1. A cytotoxic reagent comprising an antibody and a moiety having ribonucleolytic activity derived from a non-human ribonuclease.
- 2. A cytotoxic reagent comprising an internalizing antibody and a moiety having ribonucleolytic activity, wherein said internalizing antibody is directed against a lineage-dependent antigen or against an antigen associated with cancer cells.
- 3. The cytotoxic reagent of claim 2 wherein the internalizing antibody is a monoclonal antibody.
- 4. The cytotoxic reagent of claim 3 wherein the monoclonal antibody is humanized or human.
- 5. The cytotoxic reagent of claim 4 wherein the antibody is a single chain antibody.
- 6. The cytotoxic reagent of claim 5 wherein said internalizing antibody is directed against an antigen selected from the group consisting of:
  - (a) B-cell antigens;
  - (b) T-cell antigens;
  - (c) Plasma ceļļ antigens;
  - (d) HLA-DR lineage antigens;
  - (e) MUC1 antigens;
  - (f) EGP-1 antigens;
  - (g) EGP-2/antigens; and

July 2/



- 7. The cytotoxic reagent of claim 2 wherein said internalizing antibody is directed against a target antigen associated with a B- or T-cell lymphoma.
- 8. The cytotoxic reagent of claim 7 wherein said antigen is an antigen selected from the group consisting of CD19, CD22, CD40, MUC1, IL-15, HLA-DR, EGP-1, EGP-2, and IL-15.
- 9. The cytotoxic reagent of claim 8 wherein said antigen is HLA-DR.

The cytotoxic reagent of claim 2 wherein the internalizing antibody

- 11. The cytotoxic reagent of claim 8 wherein said antigen is CD22.
- 12. The cytotoxic reagent of claim 11 wherein the internalizing antibody is LL2.
- 13. The cytotoxic reagent of claim 8 wherein said antigen is MUC1.
- 14. The cytotoxic reagent of claim 13 wherein the internalizing antibody is PAM4.
- 15. The cytotoxic reagent of claim 8 wherein said antigen is EGP-1.

- 16. The cytotoxic reagent of claim 15 wherein the internalizing antibody is RS7.
- 17. The cytotoxic reagent of claim 8 wherein said antigen is EGP-2.
- 18. The cytotoxic reagent of claim 17 wherein the internalizing antibody is RS11 or 17-1A.
- 19. The cytotoxic reagent of claim 2 wherein said internalizing antibody is a lineage-dependent antibody of a B-cell.
- 20. The cytotoxic reagent of claim 2/wherein said internalizing antibody is a lineage-dependent antibody of a Troell.
- 21. The cytotoxic reagent of claim 2 wherein said internalizing antibody is a lineage-dependent antibody of a plasma cell.
- 22. The cytotoxic reagent of claim 2 wherein said antigen is CD22 or CD74.
- 23. The cytotoxic reagent of claim 2 wherein the internalizing antibody is LL1 or LL2.
- 24. A pharmaceutical composition comprising a cytotoxic reagent of claim 2 and a pharmaceutically acceptable carrier.
- 25. A method of killing cancer cells comprising administering to a subject in need thereof a pharmaceutical composition of claim 24.

54